Saetrum Opgaard O, Adner M, Gulbenkian S, Edvinsson L
Department of Internal Medicine, University Hospital of Lund, Sweden.
J Cardiovasc Pharmacol. 1994 Apr;23(4):576-83. doi: 10.1097/00005344-199404000-00009.
Strong immunoreactivity for endothelins (ETs) was observed in the endothelium of both human epicardial coronary arteries and veins. The contractile responses to ET-1, ET-2, and ET-3 were investigated in isolated circular human coronary vessel segments. ET-1, ET-2, and ET-3 induced significantly higher maximum contraction (measured in percentage of contraction induced by 60 mM potassium) and more potent responses in veins as compared with arteries. ET-1 as compared with ET-2 induced equal maximum contraction and equipotent responses both when tested in arteries and veins, whereas ET-3 induced lower maximum contraction and less potent responses in both vessel types. FR 139317, a selective ETA receptor antagonist, significantly decreased the potency of ET-1 and ET-2 responses in both human coronary arteries and veins, but the maximum effect obtained did not change significantly. The existence of ET immunoreactivity (IR) in endothelial cells from both human coronary arteries and veins indicates that ETs may be released endogenously. The effect of the selective ETA receptor antagonist FR 139317 indicates that the contraction induced by ET-1 and ET-2 in both arteries and veins is mediated by ETA receptors.
在内皮细胞中观察到人类心外膜冠状动脉和静脉的内皮素(ETs)具有强免疫反应性。在分离的人类冠状动脉环形血管段中研究了对ET-1、ET-2和ET-3的收缩反应。与动脉相比,ET-1、ET-2和ET-3在静脉中诱导出显著更高的最大收缩(以60 mM钾诱导的收缩百分比衡量)和更强的反应。与ET-2相比,ET-1在动脉和静脉中测试时诱导出相等的最大收缩和等效反应,而ET-3在两种血管类型中诱导出较低的最大收缩和较弱的反应。选择性ETA受体拮抗剂FR 139317显著降低了人类冠状动脉和静脉中ET-1和ET-2反应的效力,但获得的最大效应没有显著变化。人类冠状动脉和静脉内皮细胞中存在ET免疫反应性(IR)表明ETs可能内源性释放。选择性ETA受体拮抗剂FR 139317的作用表明,ET-1和ET-2在动脉和静脉中诱导的收缩是由ETA受体介导的。